EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DirectHRD enables sensitive scar-based classification of homologous recombination deficiency

Ruolin Liu iD, Eugenia Roberts, Heather A Parsons, Elizabeth H Stover, Atish D Choudhury, Justin Rhoades, Timothy Blewett, David D Yang, Joyce F Liu, Erica L Mayer, Viktor A Adalsteinsson

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkaf313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Ruolin Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Broad Institute of MIT and Harvard, Cambridge, MA, 02142, United States. Hauptthemen laut MEDLINE: Homologous Recombination, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Gerstner Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination deficiency (HRD) is a predictive biomarker for efficacy of PARP (poly ADP-ribose polymerase) inhibition and platinum chemotherapy for cancer patients but remains challenging to detect. The discovery of patients without pathogenic mutations in known HR genes but exhibiting genomic scars indicative of HRD led to the FDA approval of the first scar-based HRD test. Despite advancements in whole genome sequencing (WGS) and integration of large training datasets with machine learning models, current methods lack the sensitivity required for detecting HRD scars in low tumor purity samples, especially in liquid biopsies. Here, we describe DirectHRD, a genomic scar-based HRD classifier based on WGS. Compared to other WGS-based methods, DirectHRD exclusively utilizes a highly specific type of HRD scar—small deletions with microhomology—and its associated signatures in a probabilistic framework. We applied DirectHRD to 501 tumor and 90 cell-free DNA (cfDNA) samples from 4 cancer types: breast, ovarian, prostate, and pancreas. Among all 501 tumor biopsies, DirectHRD achieved 100% detection of HRD with high specificity (>90%). Across all 90 cfDNA samples, the method achieved an area under the curve of 0.87 and demonstrated the ability to detect HRD at tumor fractions as low as 1%, making it 10 times more sensitive than state-of-the-art methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homologous RecombinationNeoplasmsHumansMaleFemaleWhole Genome SequencingBiomarkers, TumorBreast NeoplasmsProstatic NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsSensitivity and Specificity

Substanzen

Biomarkers, TumorPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Broad Institute of MIT and Harvard, Cambridge, MA, 02142, United States.
  • Dana-Farber Cancer Institute, Boston, MA, 02215, United States.

ORCID-Profile: Ruolin Liu

Förderung

  • NCI NIH HHS
  • Gerstner Family Foundation

Zitieren

APA

Liu, R., Roberts, E., Parsons, H. A., Stover, E. H., Choudhury, A. D., Rhoades, J., Blewett, T., Yang, D. D., Liu, J. F., Mayer, E. L., & Adalsteinsson, V. A. (2025). DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf313

Vancouver

Liu R, Roberts E, Parsons HA, Stover EH, Choudhury AD, Rhoades J, et al. DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf313

BibTeX
@article{Liu2025,
  author = {Liu, Ruolin and Roberts, Eugenia and Parsons, Heather A and Stover, Elizabeth H and Choudhury, Atish D and Rhoades, Justin and Blewett, Timothy and Yang, David D and Liu, Joyce F and Mayer, Erica L and Adalsteinsson, Viktor A},
  title = {DirectHRD enables sensitive scar-based classification of homologous recombination deficiency},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkaf313}
}
Kostenlos starten →